Why did Galleri blood test fail?
A major multi-cancer screening trial missed its key goal
A large, high-profile trial of a multi-cancer blood test did not show the hoped-for impact on advanced disease. The study, conducted with England’s National Health Service, tested whether screening people with a blood-based multi-cancer assay would reduce the incidence of cancers detected at stage III–IV. The trial failed to meet that primary endpoint: it did not produce a statistically significant reduction in late-stage cancers.
Why the result matters
- Early detection does not automatically translate into fewer advanced cancers. A screening test must find cancers early enough and do so reliably across tumor types to change outcomes at the population level.
- The negative outcome raises questions about how blood-based multi-cancer tests should be evaluated before being rolled out widely. Sensitivity for certain cancer types, false positives, follow-up diagnostic pathways, and whether earlier detection leads to better survival all require careful assessment.
Next steps and implications
- Further analyses will examine which cancers, if any, the test detected reliably and whether any subgroups benefited. Regulators, payers and health systems will review these data before considering broader adoption.
- For clinicians and patients, the trial underscores that promising technology needs rigorous, population-based evidence showing a net benefit—not just the ability to detect tumor DNA in blood.
At present, the trial’s outcome tempers optimistic claims about a simple blood draw that can cut advanced cancer rates; it highlights the need for more targeted research, clearer diagnostic pathways after a positive test, and careful regulatory scrutiny.